Compositions And Methods For Treating Steatohepatitis, Liver Fibrosis, and Hepatocellular Carcinoma (HCC)

摘要

The invention provides methods and compositions for reducing symptoms of steatohepatitis and/or liver fibrosis and/or hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to the mammalian subject a therapeutic amount of a compound that reduces the level of interleukin 17 (IL-17) and/or interleukin 23 (IL-23) and/or signal transducer and activator of transcription 3 (Stat3) and/or Janus kinase 2 (Jak2). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of a compound that increase the level of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27). The invention's methods may comprise administering to the mammalian subject a therapeutic amount of interleukin 22 (IL-22) and/or interleukin 25 (IL-25) and/or interleukin 27 (IL-27).

主权项

1. A method for reducing one or more symptoms of one or more of steatohepatitis, liver fibrosis, and hepatocellular carcinoma (HCC) in a mammalian subject in need thereof, comprising administering to said mammalian subject a therapeutic amount of one or more compounds that reduce the level of one or more of
(a) interleukin 17 (IL-17), (b) interleukin 23 (IL-23), (c) signal transducer and activator of transcription 3 (Stat3), and (d) Janus kinase 2 (Jak2),in one or more of hepatic stellate cells (HSCs), liver resident Kupffer cells (KCs), immune cells, and inflammatory cells, wherein said therapeutic amount reduces said one or more symptoms.